A Pharmacoeconomic Comparison of Cost Variation among Hypolipidemic Drugs Available in Indian Market
Abstract
Hyperlipidemia is a major cause of atherosclerotic coronary and cerebrovascular disorders affecting a large Indian population. The cost of various hypolipidemic drugs that are used for the prevention and treatment of these afflictions largely varies in the Indian pharmaceutical market. Our study aimed to evaluate the cost variation of different brands of hypolipidemic drugs and to compare the branded prices with their corresponding generic and ceiling prices. The costs of various drugs were procured from the latest issue of the “Drug Today” from October to November 2020 edition which is a directory of all the drugs available in India published quarterly every year by Lorina Publications (India) Inc. Cost ratio, percent cost variation, and daily defined dose (DDD) were calculated. We also compared the branded prices of drugs with their generic and ceiling prices available on the official website.
A total of 9 single hypolipidemic drugs and 9 fixed-dose combinations (FDC) showed a wide per cent cost variation. The highest percentage of cost variation was atorvastatin 80 mg (3284%) whereas fenofibrate showed the lowest percent cost variation (0.91%). The cost ratio was also found higher in 2 from 6 drugs. Among FDCs, atorvastatin 10mg + ezetimibe 10 mg (484%) showed a higher cost variation and rosuvastatin 20 mg + fenofibrate 160mg (0.6%) showed a minimum variation. The maximum cost variation from branded prices compared to generic prices was found in simvastatin 20 mg (544%) and atorvastatin 10 mg (155%). In summary, our study showed a wide variation in the cost of hypolipidemic drugs available in the Indian market which provides an insight to the prescriber, gives drug price control authorities to minimize the financial burden on the patient, and improves their compliance
Keywords
Full Text:
PDFReferences
World Health Organization;c2019.Global Health Observatory(GHO) data[Internet][cited2019 Jun20].Available from:http://www.who.int/gho/ncd/mortality-morbidity/ncd-total/en/index.html).
HC,Oh SM.Non communicable diseases: Current status of major modifiable risk factors in Korea. Journal of Preventive Medicine and Public Health. 2013;46:165-172)
Gupta R, Sharma S.K. Recent trends in epidemiology of dyslipidemias in India. Indian Heart Journal.2017;69(3):382-392
Eun-Jung Rhee, Hyeon Chang Kim, In-Kyung Jeong.2018 guidelines for the management of dyslipidemia. Korean Journal of Internal Medicine. 2019;34(5):1171)]
Gurgle HE. Drug Therapy for Dyslipidemias. In: Brunton LL, Dandan RH, Kollmann BC, Eds. Goodman & Gilman The Pharmacological Basis of Therapeutics.13th ed. New York, NY: McGraw-Hill;2018: 605-618.
ACCORD Study Group.Effects of combination lipid therapy in type 2 diabetes mellitus. New England Journal Medicine. 2010,362:1563-1574).
Bureau of Pharma PSUs of India (BPPI).2020.Accessed January15,2021. http://janaushadhi.gov.in/productList.aspx.
National Pharmaceutical Pricing Authority. Government of India. Available at http://www.nppaindia.nic.in/DPCO2013.pdf.Accessed January 12, 2021
Frazier LM,Brown JT,Divine GW,Fleming GR,Philips NM,Siegal WC. Can physician education lower the cost of prescription drugs? A prospective controlled trial. Annals of Internal Medicine.1991;115(2):116-21
Guidelines for ATC Cassification and DDD Assignment.3rd ed Oslo:WHO Collaborating Center for Drug Statistics Methodology 2020.
Hypolipidemic agent. Drug today 109 Vol.No.2. July-October 2020. Lorina Publications (India) Inc. 867-873.
Tiwari A, Reddy P. Cost analysis of Antifungal drugs available in India: A pharmacoeconomic perspective. Indian Journal of Pharmacy and Pharmacology. October-December 2016; 3(4); 192-196
Rao KS, Nundy M, Dua A S. National commission on macroeconomics and health. Financing and delivery of health care services in India. New Delhi: Ministry of health and family welfare. Government of India. Delivery of health in the private sector. 2005, 89-104.
Cholesterol Treatment Trialists (CTT) collaboration.Baigent C,Blackwell L,.Efficacy and safety of more intensive lowering of LDL cholesterol:A meta analysis of data from 170000 participants in 26 randomized trials. Lancet. 2010;376:1670-1681).
Oscar H F, Peters A. Cost effectiveness of statins in chronic heart disease. Journal of epidemiology and community health, 2005; 59(11).http..// jech.bmj.com/content/59/11/927
Padmavathi V, Kranti T.Analysis of cost variation among various statin preparations available in India. Indian Journal of Pharmacy and Pharmacology.Jan-Mar,2019;6(1):14-17
Sreedevi K. Venkateswara Rao. J. A study on prescription pattern of statins in cardiovascular disease; January 2011 Der Pharmacia letter 3(3):393-396
Dean G S, Christopher R MB. An economic analysis of the Atorvastatin comparative efficacy and safety study (ACCESS). Pharmacoeconomics. 2003; 21suppl1:13-23.
Carlo S. Clinical trials with Rosuvastatin: efficacy and safety of its use. Italian Heart Journal. 2003 Dec; 4 suppl 7:33s-46s.
Vavlukis M, Vavlukis A. Adding Ezetimibe to Statin Therapy: latest evidence and clinical implications. Drugs in Context. 2018; 7:212534
DOI: https://doi.org/10.15416/pcpr.v6i3.32488
Refbacks
- There are currently no refbacks.
